Efficacy of Wharton Jelly in Erectile Dysfunction

Erectile Dysfunction Associated With Type 2 Diabetes Mellitus Clinical Trial

Official title: Evaluation of the Efficacy for Two Doses of Intracavernous Injection of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction

Status Completed

Clinical Trial Summary

Efficacy of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.

Clinical Trial Description

This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which 22 male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests.

The patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound.

The investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients. ;

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Erectile Dysfunction
• Erectile Dysfunction Associated With Type 2 Diabetes Mellitus

• NCT number: NCT03751735
• Study type: Interventional
• Source: University of Jordan
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 27, 2017
• Completion date: February 26, 2019